FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018658265> ?p ?o ?g. }

• W2018658265 endingPage "421" @default.
• W2018658265 startingPage "417" @default.
• W2018658265 abstract "To determine the activity of capecitabine in women with platinum-resistant ovarian cancer.In this multi-centre phase II trial, 35 patients with platinum-resistant ovarian, primary peritoneal or fallopian tube carcinomas were treated with capecitabine 1250 mg/m(2) twice daily for 14 days every 21 days. Platinum resistance was defined as progression within 4 months of completing the last platinum and all patients had previously received a taxane. Response was assessed by both RECIST criteria for patients with measurable disease and CA125 criteria. Responders were defined as patients with measurable disease who achieved a CR or PR according to RECIST criteria, patients without measurable disease who met the CA125 criteria for response and patients with stable measurable disease who met the CA125 criteria for response.Patients had received a median of four prior chemotherapy regimens (range 1-9). The median number of cycles of capecitabine administered was 3 (range 1-10). The response rate using the combined RECIST and CA125 criteria was 9% (95% CI 2-25%). In patients evaluable using RECIST criteria, the response rate was 5% (95% CI 0-25%). In patients evaluable for CA125 response, the response rate was 7% (95% CI 1-22%). The median progression-free survival was 2.3 months, and the median survival was 7.1 months. Treatment was generally well tolerated with most frequent grade 3 toxicities being hand-foot syndrome (17%) and diarrhea (9%).Capecitabine is well tolerated but has limited activity in patients with heavily pre-treated platinum-resistant ovarian cancer." @default.
• W2018658265 created "2016-06-24" @default.
• W2018658265 creator A5010965225 @default.
• W2018658265 creator A5021894535 @default.
• W2018658265 creator A5039888939 @default.
• W2018658265 creator A5044583406 @default.
• W2018658265 creator A5060469120 @default.
• W2018658265 creator A5074802129 @default.
• W2018658265 creator A5086460858 @default.
• W2018658265 date "2004-05-01" @default.
• W2018658265 modified "2023-09-25" @default.
• W2018658265 title "A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer" @default.
• W2018658265 cites W1543697093 @default.
• W2018658265 cites W1878670617 @default.
• W2018658265 cites W1919810009 @default.
• W2018658265 cites W192761810 @default.
• W2018658265 cites W1960327677 @default.
• W2018658265 cites W1967226630 @default.
• W2018658265 cites W1972938770 @default.
• W2018658265 cites W1990319096 @default.
• W2018658265 cites W2006787885 @default.
• W2018658265 cites W2010282089 @default.
• W2018658265 cites W2063016188 @default.
• W2018658265 cites W2068513410 @default.
• W2018658265 cites W2105782281 @default.
• W2018658265 cites W2108703276 @default.
• W2018658265 cites W2136753100 @default.
• W2018658265 cites W2136788689 @default.
• W2018658265 cites W2139248078 @default.
• W2018658265 cites W2151050516 @default.
• W2018658265 cites W2167197605 @default.
• W2018658265 cites W2176556095 @default.
• W2018658265 cites W2328421677 @default.
• W2018658265 cites W2418276562 @default.
• W2018658265 cites W3035130918 @default.
• W2018658265 cites W2067383190 @default.
• W2018658265 doi "https://doi.org/10.1016/j.ygyno.2004.01.037" @default.
• W2018658265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15099955" @default.
• W2018658265 hasPublicationYear "2004" @default.
• W2018658265 type Work @default.
• W2018658265 sameAs 2018658265 @default.
• W2018658265 citedByCount "20" @default.
• W2018658265 countsByYear W20186582652015 @default.
• W2018658265 countsByYear W20186582652017 @default.
• W2018658265 countsByYear W20186582652018 @default.
• W2018658265 countsByYear W20186582652022 @default.
• W2018658265 crossrefType "journal-article" @default.
• W2018658265 hasAuthorship W2018658265A5010965225 @default.
• W2018658265 hasAuthorship W2018658265A5021894535 @default.
• W2018658265 hasAuthorship W2018658265A5039888939 @default.
• W2018658265 hasAuthorship W2018658265A5044583406 @default.
• W2018658265 hasAuthorship W2018658265A5060469120 @default.
• W2018658265 hasAuthorship W2018658265A5074802129 @default.
• W2018658265 hasAuthorship W2018658265A5086460858 @default.
• W2018658265 hasConcept C121608353 @default.
• W2018658265 hasConcept C126322002 @default.
• W2018658265 hasConcept C141071460 @default.
• W2018658265 hasConcept C143998085 @default.
• W2018658265 hasConcept C2776694085 @default.
• W2018658265 hasConcept C2777511904 @default.
• W2018658265 hasConcept C2777909004 @default.
• W2018658265 hasConcept C2778822529 @default.
• W2018658265 hasConcept C2779984678 @default.
• W2018658265 hasConcept C2780427987 @default.
• W2018658265 hasConcept C2780739268 @default.
• W2018658265 hasConcept C526805850 @default.
• W2018658265 hasConcept C530470458 @default.
• W2018658265 hasConcept C71924100 @default.
• W2018658265 hasConcept C90924648 @default.
• W2018658265 hasConceptScore W2018658265C121608353 @default.
• W2018658265 hasConceptScore W2018658265C126322002 @default.
• W2018658265 hasConceptScore W2018658265C141071460 @default.
• W2018658265 hasConceptScore W2018658265C143998085 @default.
• W2018658265 hasConceptScore W2018658265C2776694085 @default.
• W2018658265 hasConceptScore W2018658265C2777511904 @default.
• W2018658265 hasConceptScore W2018658265C2777909004 @default.
• W2018658265 hasConceptScore W2018658265C2778822529 @default.
• W2018658265 hasConceptScore W2018658265C2779984678 @default.
• W2018658265 hasConceptScore W2018658265C2780427987 @default.
• W2018658265 hasConceptScore W2018658265C2780739268 @default.
• W2018658265 hasConceptScore W2018658265C526805850 @default.
• W2018658265 hasConceptScore W2018658265C530470458 @default.
• W2018658265 hasConceptScore W2018658265C71924100 @default.
• W2018658265 hasConceptScore W2018658265C90924648 @default.
• W2018658265 hasIssue "2" @default.
• W2018658265 hasLocation W20186582651 @default.
• W2018658265 hasLocation W20186582652 @default.
• W2018658265 hasOpenAccess W2018658265 @default.
• W2018658265 hasPrimaryLocation W20186582651 @default.
• W2018658265 hasRelatedWork W1980082967 @default.
• W2018658265 hasRelatedWork W2008972782 @default.
• W2018658265 hasRelatedWork W2016016176 @default.
• W2018658265 hasRelatedWork W2018658265 @default.
• W2018658265 hasRelatedWork W2073169852 @default.
• W2018658265 hasRelatedWork W2147013188 @default.
• W2018658265 hasRelatedWork W2392230653 @default.
• W2018658265 hasRelatedWork W2590140540 @default.
• W2018658265 hasRelatedWork W2944015322 @default.

• next